OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Assessing immunogenicity barriers of the HIV-1 envelope trimer	202
Reverse development of vaccines against antimicrobial-resistant pathogens	136
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization	122
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	118
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	115
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	109
Mapping global public perspectives on mRNA vaccines and therapeutics	99
The dengue-specific immune response and antibody identification with machine learning	94
Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle	94
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	82
Protein engineering strategies for rational immunogen design	78
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	75
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development	68
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	65
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle	65
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	63
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	61
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice	59
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants	59
Rational development of a combined mRNA vaccine against COVID-19 and influenza	59
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity	59
Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates	59
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine	59
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition	58
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants	58

Leishmania tarentolae as a platform for the production of vaccines against viral pathogens	57
Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2	55
A field test of empathetic refutational and motivational interviewing to address vaccine hesitancy among patients	52
Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination	52
A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens	51
LmCen−/− based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia	47
Antibody responses against influenza A decline with successive years of annual influenza vaccination	47
Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox	47
Author Correction: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax	47
Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum	46
Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses	46
Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins	46
Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen	46
A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark	45
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen	44
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus	44
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex	43
IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development	42
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine	42